BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors


August 30, 2021

  • ImmixBio to assess the safety, tolerability, and efficacy of IMX-110 in combination with tislelizumab in a P-I/IIa trial in patients with advanced solid tumors
  • The novel approach of combining ImmixBio’s tissue specific therapeutics (TSTx) with immunotherapies could expand the population of cancer patients experiencing extended remissions
  • The pre-clinical studies showed IMX-110 turns “cold” tumors “hot,” and IMX-110 + murine anti-PD-1 demonstrated extended survival in a genetic mouse model of pancreatic cancer vs multi-drug combinations in the literature showed substantial rationale to combine IMX-110 and tislelizumab

Original Article Link